OncoMatch/Clinical Trials/NCT04989647

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy

Is NCT04989647 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for cervical cancer.

Phase 3RecruitingThe Central and Eastern European Gynecologic Oncology GroupNCT04989647Data as of May 2026

The objective of the trial is to evaluate if adjuvant (chemo)radiation is associated with a disease-free survival benefit after radical surgery in patients with intermediate risk cervical cancer. The primary endpoint of the study is the disease-free survival from the day of randomisation. A total of 514 patients are required to achieve 80% power on 5% significance level with non-inferiority margin of 5% to test the difference between the ARMs using Cox proportional hazards model. The maximal tolerated margin for non-inferiority in 2-year DFS is 5% (including expected drop-out rate of 10%).

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Disease stage

Required: Stage IIA (FIGO)

Excluded: Stage <IB1, >IIA

FIGO IB1-IIA

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: pelvic radiotherapy

Cannot have received: neoadjuvant chemotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify